Stifel analyst Rick Wise raised the firm’s price target on Baxter to $56 from $54 and keeps a Buy rating on the shares ahead of the company’s Q2 report due on July 27. The firm argues that the stage is set positively for Baxter to “regress to the mean” fundamentally with possible early signs of more-consistent performance as well as several growth-accelerating and margin-improving catalysts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BAX: